Stock Market Reviews

XBIO (Xenetic Biosciences, Inc.) News

Get the latest news, insights, and market updates on XBIO (Xenetic Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
  Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company ...
  Dec 11, 2025 - $XBIO
• Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
  FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, ...
  Nov 19, 2025 - $XBIO
• Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
  Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners Secured net proceeds of approximately $3.9 million from October 2025 offering FRAMINGHAM, MA / ACCESS Newswire / November 13, 2025 /Xenetic ...
  Nov 13, 2025 - $XBIO
• Xenetic Biosciences: Q3 Earnings Snapshot
  FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Wednesday reported a loss of $510,000 in its third quarter.
  Nov 12, 2025 - $XBIO
• Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
  Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 30, 2025 - $XBIO
• Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
  FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, ...
  Oct 10, 2025 - $XBIO
• Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
  Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the quarter with $4.8 million of cash to fund operations ...
  Aug 13, 2025 - $XBIO
• Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
  Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 12, 2025 - $XBIO
• Xenetic Biosciences: Q2 Earnings Snapshot
  FRAMINGHAM, Mass. AP) — Xenetic Biosciences, Inc. XBIO) on Tuesday reported a loss of $689,000 in its second quarter.
  Aug 12, 2025 - $XBIO
• Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
  Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical ...
  Jul 30, 2025 - $XBIO